{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.35","upperLimit":"240","value":"1.48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Time from registration to the earliest date with documentation of disease progression, assessed up to 1 year. The distribution of time to progression will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 650 mg Acetaminophen and 50 mg Benadryl orally 30 minutes prior to MV-NIS then receive MV-NIS IV over 1 hour on day 1.","id":"OG000","title":"Phase II (Acetaminophen + Benadryl + MV-NIS)"}],"paramType":"MEDIAN","populationDescription":"Phase II specified secondary endpoint will only include Phase II patients. Phase II Cohort A and Phase II Cohort B were combined for this analysis due to accrual terminating in Cohort B early and to get the overall TTP for Phase II patients.","reportingStatus":"POSTED","timeFrame":"Time from registration to the earliest date with documentation of disease progression, assessed up to 1 year","title":"Time to Progression (TTP) (Phase II)","type":"SECONDARY","unitOfMeasure":"months"}